Iclaprim Proves Effective for ABSSSIs in Patients with Diabetes With Fewer Adverse Effects
September 20th 2018Patients with diabetes who were treated for acute bacterial skin and skin structure infections (ABSSSIs) with iclaprim had fewer adverse events (AEs) than those who were treated with vancomycin, according to the results of a recent study.
Read More